|
|
Vaccine Detail
|
Recombinant Anti-WT1 Immunotherapeutic GSK2302024A Vaccine |
| Vaccine Information |
- Vaccine Name: Recombinant Anti-WT1 Immunotherapeutic GSK2302024A Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007013
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: WT1
- WT1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: This is for Breast Cancer (NCT01220128). An immunotherapeutic composed of the Wilms tumor 1 (WT1) and an as of yet undisclosed adjuvant, with potential antineoplastic activity. Upon administration, the immune system may be stimulated to exert a cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells. The adjuvant stimulates the immune system's response to WT1. WT1, a tumor-associated antigen (TAA) and transcription factor, is overexpressed in a variety of tumor cell types (NCIT_C116880).
|
| Host Response |
|
|
| References |
NCIT_C116880: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C116880]
NCT01220128: [https://clinicaltrials.gov/show/NCT01220128/]
|
|
